Baird analyst Brian Skorney lowered the firm’s price target on Applied Therapeutics (APLT) to $5 from $14 and keeps an Outperform rating on the shares after the FDA issued a complete response letter for govorestat for the treatment of galactosemia. The “credibility damage will be tough to bounce back from” there is a lack of substantial detail around how the review went south, the analyst tells investors in a research note. The firm now expects the review in sorbitol dehydrogenase deficiency to be “greeted with much greater skepticism by investors.” However, it remains an attractive a commercial opportunity as galactosemia and the stock could rally back in the double-digits after an approval next year, contends Baird.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLT:
- Unusually active option classes on open November 29th
- Voyager upgraded, HP downgraded: Wall Street’s top analyst calls
- Voyager rises after upgrade, Applied plunges after CRL: Morning Movers
- Applied Therapeutics CRL a ‘major setback,’ says William Blair
- Applied Therapeutics downgraded to Sector Perform from Outperform at RBC
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
